Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
NOTRELOAD AI
William Blair Bullish on Beam Therapeutics Following Strategic Update
William Blair maintains Outperform rating on Beam Therapeutics after company announces FDA alignment for BEAM-302 and planned risto-cel application, citing clear regulatory pathway ahead.
Abercrombie & Fitch Shares Drop as Holiday Sales Miss Expectations
Abercrombie & Fitch stock plunged after disappointing holiday sales results, triggering a broader selloff in retail stocks including American Eagle and Urban Outfitters.
Chinese Food Delivery Stocks Jump on Regulatory Probe Into Price Wars
Chinese food delivery stocks surge as regulators investigate price wars. Meituan, Alibaba, and JD.com rally on hopes authorities will end costly subsidy battles.
Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
FDA Rejects Atara's Cancer Treatment Application
Atara Biotherapeutics (ATRA) receives second FDA rejection for EBVALLO cancer therapy despite resolving manufacturing issues, citing concerns about clinical trial design.